Raise Capital
Products
Resources
January 17, 2023
Raised through Reg A+
New investors onboarded
Successfully uplisted
Digital warrant processing
Draganfly is a leading provider of advanced aerial imaging technology and unmanned aerial vehicles (UAVs). The company's state-of-the-art UAVs are used in a wide range of applications, including mapping, surveying, and inspection.
Draganfly was already listed on the OTC market when it decided to raise capital through a Reg A+ offering to fuel its growth and expand its technological capabilities.
To manage the complex process of raising capital from a large number of retail investors, Draganfly needed a sophisticated and reliable platform. The company faced several distinct challenges:
Finding a platform that could address all these needs while maintaining compliance and providing a seamless investor experience was critical to Draganfly's capital-raising strategy.
Draganfly turned to DealMaker, whose platform made it easy to manage the influx of investors and their investment funds. DealMaker's intuitive interface allowed Draganfly to quickly and easily create and manage investment tickets, ensuring that each investor was allocated the correct amount of capital.
The success of Draganfly's Reg A+ offering allowed the company to use the momentum of the offering to list on NASDAQ. The marketing that the company did for the Reg A+ offering also helped to generate interest in the company's stock, increasing its visibility among investors.
Draganfly's partnership with DealMaker resulted in a highly successful capital raise that provided the foundation for the company's continued growth and NASDAQ listing:
DealMaker is the only platform that currently processes warrant exercises digitally—transforming an incredibly complicated task into a smooth, efficient process. The intuitive interface and powerful tools of DealMaker's technology make it easy to handle these complex processes, ensuring that investors are able to exercise their warrants smoothly and efficiently.
From Reg A+, to warrants, to their NASDAQ listing - Draganfly has had an incredibly successful journey for raising capital and acquiring investors. DealMaker's technology helped to turn complex processes into an easy and intuitive digital interface. As a result, Draganfly has been able to raise the capital it needs to continue its growth and expansion, and to increase its visibility among investors.
DealMaker and its affiliates neither offer investment advice or analysis nor endorse or recommend investments in any company or the suitability of an investment for any particular investor. The information on our website regarding any company or in a website post is based on publicly available information or directly from the subject company. DealMaker and its affiliates make no representation or warranty as to the adequacy, accuracy, or completeness of such information. Any comments expressed herein are our own, are not intended as investment advice, and are subject to change without notice. Website posts have been prepared solely for informative purposes and are not a solicitation of an offer to buy or an offer to sell any security.
Monogram Technologies was founded with a bold vision: to revolutionize orthopedic surgery with a robotic joint replacement system using custom 3D-printed joints. The market for this technology is massive—approximately $19.6 billion, with over 1 million knee replacements per year. But it's a capital-intensive, regulation-heavy space—and traditional VCs weren't biting.
Instead of compromising, co-founders Dr. Doug Unis and Ben Sexson went all-in on a different path: retail capital. Why?
Start Date | End Date | Type | Platform | Amount Raised | # Investors |
---|---|---|---|---|---|
3/13/19 | 3/31/20 | A+ | SeedInvest | $14,588,668 | 6,000 |
11/16/20 | 1/16/21 | A+ | StartEngine | $2,965,501 | 8,000 |
1/17/21 | 2/18/22 | A+ | StartEngine | $23,647,853 | 14,082 |
7/15/22 | 3/16/23 | CF | DealMaker | $4,673,000 | 2,249 |
3/1/23 | 4/8/23 | A+ | Republic | $232,275 | 120 |
3/1/23 | 5/23/23 | A+ | DealMaker | $15,958,364 | 5,198 |
5/18/23 | - | Nasdaq listing | |||
7/24 | 10/24 | Unit Offering | DealMaker | $12,990,103 | 2,745 |
Monogram's first direct-to-investor raise was a $14.6M round in 2019. Since then, Monogram has raised retail capital six additional times, using Reg A+ as a springboard to a Nasdaq listing in 2023.
Each raise brought in new believers—and more importantly, kept bringing them back. That's the long-term power of retail capital. It's not just one campaign—it's a compounding asset that grows with the business.
DealMaker Reach provided strategic investor acquisition services, helping Monogram connect with the right audience through high-impact channels.
Targeted campaigns in premium publications like Morning Brew captured qualified investors
Engaging events that generated over $4.3 million in investments
Strategic approaches that fostered a loyal shareholder base
Innovative approaches that amplified investment momentum
Monogram's journey has been defined by relentless innovation, strategic fundraising, and breakthrough advancements in robotic-assisted joint replacement. From early-stage research to a Nasdaq listing and beyond, Monogram's milestones reflect its evolution into a pioneering force in orthopedic surgery:
In May 2023, Monogram Orthopaedics successfully listed on the Nasdaq—a significant milestone offering liquidity and growth opportunities for the company.
For most companies, that would be the end of their story in the private markets. But for Monogram, it was just the beginning of a new chapter.
Public perception says you can't raise privately post-IPO. Monogram proved that wrong.
Defying conventional fundraising norms, Monogram raised an additional $13 million from private investors, powered by DealMaker. This move highlighted the power of a dedicated investor community and provided additional strategic growth capital. Meanwhile, strategic digital marketing for the private offering helped boost the public share price—a win-win for the company and its investors, both public and private.
The strategic private offering conducted through DealMaker helped drive awareness and interest in Monogram's public shares, contributing to positive market performance during the raise period.
This was retail capital at its best: strategic, repeatable, and aligned.
This wasn't a one-time raise. It was a multi-year capital strategy.
Retail capital helped Monogram:
This is what makes retail capital different. It doesn't expire—it compounds. And DealMaker is built to maximize that long-term value.
Whether you're pre-revenue or post-IPO, DealMaker gives you the infrastructure, support, and strategy to raise from the people who believe in you most.
Explore Raising Capital with DealMaker